Disease Info Card

Radiation Chimera Disorder

Information about Radiation Chimera Disorder: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Radiation Chimera Disorder

Most recent studies have shown that Radiation Chimera Disorder shares some biological mechanisms with anemia, autoimmune-diseases, autoimmune-reaction, cell-transformation-neoplastic, chimera-disorder, decreased-immunologic-activity-[pe], delayed-hypersensitivity, graft-vs-host-disease, graft-vs-host-reaction, immunologic-deficiency-syndromes, immunologic-tolerance, inflammation, leukemia, leukemia-experimental, lymphoma, malignant-neoplasms, neoplasms, neoplasms-experimental, radiation-injuries-experimental, severe-combined-immunodeficiency.

Among the many pathways, these few ones have gauged particular interests from scientists studying Radiation Chimera Disorder, and have been seen in publications frequently: Cell Activation, Cell Cycle, Cell Death, Cell Development, Cell Differentiation, Cell Maturation, Cell Proliferation, Cytokine Production, Hemopoiesis, Humoral Immune Response, Hypersensitivity, Immune Response, Localization, Pathogenesis, Regeneration, Secretion, Sensitization, T Cell Activation, T Cell Differentiation, Tolerance Induction

Quite a number of genes have been found to play important roles in Radiation Chimera Disorder, such as ATN1, CD34, CD4, CD8A, CSF3, CTLA4, ENPP3, HLA-DQA1, HLA-E, IFNG, IL2, IL3, IL4, IL6, KITLG, NOD2, PTPRC, TNF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.